HealthQuill Novo Nordisk
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people with type 1 diabetes, with seven members voting for and four against.
Drugs Health Pharma

FDA panel rejects Novo Nordiskā€™s weekly jab to treat type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.

Read More
Novo Nordisk, Europeā€™s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.
Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europeā€™s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

Read More
US-based biotechnology company Viking Therapeutics Inc., reported ā€œpositiveā€ results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.
Drugs Health Pharma

Viking Therapeuticsā€™ weight-loss drug shows ā€˜positiveā€™ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported ā€œpositiveā€ results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More
Novo Nordisk, one of the worldā€™s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).
Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the worldā€™s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

Read More
Obesity is a health risk that needs to be tackled worldwide
Drugs Health Pharma

Novo Nordisk unveils new drug to fight obesity, says 13% effective

HQ Team March 11, 2024: Danish drugmaker Novo Nordiskā€™s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.

Read More
Novo Nordiskā€™s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24% of people involved in trials, the company announced.
Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progressionĀ 

HQ Team March 6, 2024: Novo Nordiskā€™s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

Read More
Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.
Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

Read More
Denmarkā€™s Novo Nordisk declared its late-stage experimental once-weekly diabetes drugĀ IcoSema achieved its primary endpoint of proving ā€œnon-inferiorityā€ in lowering blood sugar levels.
Drugs Health Pharma

Novo Nordisk diabetes drug meets trial goals against insulin glargine

Ā HQ Team January 9, 2023: Denmarkā€™s Novo Nordisk declared its late-stage experimental once-weekly diabetes drugĀ IcoSema achieved its primary endpoint of proving ā€œnon-inferiorityā€ in.

Read More
The FDA has seized ā€œthousands of unitsā€ of counterfeit weight-loss injection Ozempic which have no information about the drugā€™s identity, quality or safety.
Drugs Health Pharma

FDA starts crackdown against fake Ozempic weight-loss drugĀ 

HQ Team December 22, 2023: The FDA has seized ā€œthousands of unitsā€ of counterfeit weight-loss injection Ozempic which have no information about the.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

Read More